<p>Merus（NASDAQ:MRUS - 獲取免費報告）的股票在週三的報告中被 Weiss Ratings 的股票研究人員重新評定為 “賣出（d-）” 評級，Weiss Ratings 報道。</p>
<p>其他股票研究分析師也對該股票發佈了報告。Guggenheim 在 9 月 30 日（星期二）的報告中重新評定為 “中性” 評級，並將 Merus 的目標價格從 109.00 美元下調至 97.00 美元。Truist Financial 將 Merus 的評級從 “買入” 下調至 “持有”，並在 9 月 29 日（星期一）的報告中將其目標價格從 88.00 美元提高至 97.00 美元。瑞銀集團在 9 月 30 日（星期二）的報告中將 Merus 的評級從 “買入” 下調至 “中性”，並將其目標價格從 72.00 美元提高至 97.00 美元。工業聯盟證券在 8 月 25 日（星期一）的報告中對 Merus 的目標價格設定為 90.00 美元。最後，Canaccord Genuity Group 在 9 月 29 日（星期一）的報告中將 Merus 的評級從 “買入” 下調至 “持有”，並將其目標價格從 67.00 美元提高至 97.00 美元。四位投資分析師對該股票給予 “買入” 評級，十四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Merus 目前的平均評級為 “持有”，平均目標價格為 93.12 美元。</p>
<p><strong>獲取我們關於 Merus 的最新研究報告</strong></p>
<h2>Merus 股票下跌 0.0%</h2>
<p>週三，NASDAQ MRUS 的開盤價為 94.38 美元。Merus 的 52 周最低價為 33.19 美元，52 周最高價為 94.56 美元。該公司的市值為 71.4 億美元，市盈率為-17.16，貝塔值為 1.26。該公司的 50 日移動平均價格為 71.20 美元，200 日移動平均價格為 57.01 美元。</p>
<p>Merus（NASDAQ:MRUS - 獲取免費報告）最近在 8 月 5 日（星期二）發佈了季度財報。這家生物技術公司報告的季度每股收益為（2.23 美元），低於市場共識預期的（1.17 美元）1.06 美元。該季度的營業收入為 883 萬美元，而分析師預期為 977 萬美元。Merus 的淨利潤率為-685.64%，股本回報率為-50.28%。作為一個整體，股票研究分析師預計 Merus 在本年度將發佈-3.85 美元的每股收益。</p>
<h2>內部人士下注</h2>
<p>在其他 Merus 新聞中，首席運營官 Peter B. Silverman 在 7 月 17 日（星期四）出售了 25,000 股公司的股票。該股票以 60.00 美元的平均價格出售，總價值為 1,500,000.00 美元。該交易在證券交易委員會的備案中披露，相關信息可通過此超鏈接獲取。3.70% 的股票由內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>對沖基金和其他機構投資者最近修改了對該公司的持股。GAMMA Investing LLC 在第一季度將其在 Merus 的持股比例提高了 2,153.6%。GAMMA Investing LLC 現在擁有 631 股生物技術公司的股票，價值 27,000 美元，此前在上個季度增持了 603 股。CWM LLC 在第二季度將其在 Merus 的持股比例提高了 299.0%。CWM LLC 現在擁有 802 股生物技術公司的股票，價值 42,000 美元，此前在上個季度增持了 601 股。GF Fund Management CO. LTD.在第一季度將其在 Merus 的持股比例提高了 21.9%。GF Fund Management CO. LTD.現在擁有 1,753 股生物技術公司的股票，價值 74,000 美元，此前在上個季度增持了 315 股。Caitong International Asset Management Co. Ltd 在第一季度將其在 Merus 的持股比例提高了 955.3%。Caitong International Asset Management Co. Ltd 現在擁有 1,794 股生物技術公司的股票，價值 76,000 美元，此前在上個季度增持了 1,624 股。最後，Mirae Asset Global Investments Co. Ltd.在第二季度將其在 Merus 的持股比例提高了 15.7%。Mirae Asset Global Investments Co. Ltd.現在擁有 2,674 股生物技術公司的股票，價值 141,000 美元，此前在上個季度增持了 362 股。目前 96.14% 的股票由機構投資者持有。</p>
<h2>Merus 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Merus N.V.是一家臨牀階段的免疫腫瘤學公司，專注於在荷蘭開發抗體治療。其雙特異性抗體候選藥物管線包括 Zenocutuzumab（MCLA-128），該藥物正在進行針對轉移性乳腺癌和去勢抵抗性前列腺癌患者的二期臨牀試驗，同時也在進行針對攜帶 Neuregulin 1 的實體腫瘤的 1/2 期臨牀試驗。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Merus 更好</li>
<li>股票中的死亡交叉是什麼？</li>
<li>5 只醫療保健股票推動該行業的大反彈</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>火箭實驗室：一家太空巨頭創下新高——現在是追逐的時候嗎？</li>
<li>2025 年有潛力上漲的 2 只 CRM 平台股票</li>
<li>Lowe’s 與 Home Depot：哪家從降低利率中受益更多？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Merus 嗎？</h2>
<p>在考慮 Merus 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Merus 並不在名單上。</p>
<p>雖然 Merus 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

MRUS

<p>Weiss Ratings 在週三的一份研究報告中重申了對 Merus 股票的 “賣出（d-）” 評級</p>

<p>Merus (NASDAQ:MRUS - Get Free Report)'s stock had its &#34;sell (d-)&#34; rating reissued by equities researchers at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.</p>
<div class="lb-trans"><p>Merus（NASDAQ:MRUS - 獲取免費報告）的股票在週三的報告中被 Weiss Ratings 的股票研究人員重新評定為 “賣出（d-）” 評級，Weiss Ratings 報道。</p>
</div><p>Other equities research analysts have also issued reports about the stock. Guggenheim reissued a &#34;neutral&#34; rating and issued a $97.00 target price (down from $109.00) on shares of Merus in a report on Tuesday, September 30th. Truist Financial lowered shares of Merus from a &#34;buy&#34; rating to a &#34;hold&#34; rating and increased their target price for the stock from $88.00 to $97.00 in a report on Monday, September 29th. UBS Group lowered shares of Merus from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and increased their target price for the stock from $72.00 to $97.00 in a report on Tuesday, September 30th. Industrial Alliance Securities set a $90.00 target price on shares of Merus in a report on Monday, August 25th. Finally, Canaccord Genuity Group lowered shares of Merus from a &#34;buy&#34; rating to a &#34;hold&#34; rating and increased their target price for the stock from $67.00 to $97.00 in a report on Monday, September 29th. Four investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Merus currently has an average rating of &#34;Hold&#34; and an average price target of $93.12.</p>
<div class="lb-trans"><p>其他股票研究分析師也對該股票發佈了報告。Guggenheim 在 9 月 30 日（星期二）的報告中重新評定為 “中性” 評級，並將 Merus 的目標價格從 109.00 美元下調至 97.00 美元。Truist Financial 將 Merus 的評級從 “買入” 下調至 “持有”，並在 9 月 29 日（星期一）的報告中將其目標價格從 88.00 美元提高至 97.00 美元。瑞銀集團在 9 月 30 日（星期二）的報告中將 Merus 的評級從 “買入” 下調至 “中性”，並將其目標價格從 72.00 美元提高至 97.00 美元。工業聯盟證券在 8 月 25 日（星期一）的報告中對 Merus 的目標價格設定為 90.00 美元。最後，Canaccord Genuity Group 在 9 月 29 日（星期一）的報告中將 Merus 的評級從 “買入” 下調至 “持有”，並將其目標價格從 67.00 美元提高至 97.00 美元。四位投資分析師對該股票給予 “買入” 評級，十四位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat.com 的數據，Merus 目前的平均評級為 “持有”，平均目標價格為 93.12 美元。</p>
</div><p><strong>Get Our Latest Research Report on Merus</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Merus 的最新研究報告</strong></p>
</div><h2>Merus Stock Down 0.0%</h2>
<div class="lb-trans"><h2>Merus 股票下跌 0.0%</h2>
</div><p>NASDAQ MRUS opened at $94.38 on Wednesday. Merus has a 52 week low of $33.19 and a 52 week high of $94.56. The firm has a market capitalization of $7.14 billion, a P/E ratio of -17.16 and a beta of 1.26. The company has a 50-day moving average price of $71.20 and a 200-day moving average price of $57.01.</p>
<div class="lb-trans"><p>週三，NASDAQ MRUS 的開盤價為 94.38 美元。Merus 的 52 周最低價為 33.19 美元，52 周最高價為 94.56 美元。該公司的市值為 71.4 億美元，市盈率為-17.16，貝塔值為 1.26。該公司的 50 日移動平均價格為 71.20 美元，200 日移動平均價格為 57.01 美元。</p>
</div><p>Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biotechnology company reported ($2.23) EPS for the quarter, missing the consensus estimate of ($1.17) by ($1.06). The business had revenue of $8.83 million for the quarter, compared to analysts' expectations of $9.77 million. Merus had a negative net margin of 685.64% and a negative return on equity of 50.28%. As a group, equities research analysts anticipate that Merus will post -3.85 EPS for the current year.</p>
<div class="lb-trans"><p>Merus（NASDAQ:MRUS - 獲取免費報告）最近在 8 月 5 日（星期二）發佈了季度財報。這家生物技術公司報告的季度每股收益為（2.23 美元），低於市場共識預期的（1.17 美元）1.06 美元。該季度的營業收入為 883 萬美元，而分析師預期為 977 萬美元。Merus 的淨利潤率為-685.64%，股本回報率為-50.28%。作為一個整體，股票研究分析師預計 Merus 在本年度將發佈-3.85 美元的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other Merus news, COO Peter B. Silverman sold 25,000 shares of the company's stock in a transaction that occurred on Thursday, July 17th. The stock was sold at an average price of $60.00, for a total value of $1,500,000.00. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. 3.70% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他 Merus 新聞中，首席運營官 Peter B. Silverman 在 7 月 17 日（星期四）出售了 25,000 股公司的股票。該股票以 60.00 美元的平均價格出售，總價值為 1,500,000.00 美元。該交易在證券交易委員會的備案中披露，相關信息可通過此超鏈接獲取。3.70% 的股票由內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds and other institutional investors have recently modified their holdings of the company. GAMMA Investing LLC boosted its position in shares of Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 603 shares during the last quarter. CWM LLC boosted its position in shares of Merus by 299.0% during the 2nd quarter. CWM LLC now owns 802 shares of the biotechnology company's stock valued at $42,000 after acquiring an additional 601 shares during the last quarter. GF Fund Management CO. LTD. boosted its position in shares of Merus by 21.9% during the 1st quarter. GF Fund Management CO. LTD. now owns 1,753 shares of the biotechnology company's stock valued at $74,000 after acquiring an additional 315 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 1,624 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Merus by 15.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company's stock valued at $141,000 after acquiring an additional 362 shares during the last quarter. 96.14% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>對沖基金和其他機構投資者最近修改了對該公司的持股。GAMMA Investing LLC 在第一季度將其在 Merus 的持股比例提高了 2,153.6%。GAMMA Investing LLC 現在擁有 631 股生物技術公司的股票，價值 27,000 美元，此前在上個季度增持了 603 股。CWM LLC 在第二季度將其在 Merus 的持股比例提高了 299.0%。CWM LLC 現在擁有 802 股生物技術公司的股票，價值 42,000 美元，此前在上個季度增持了 601 股。GF Fund Management CO. LTD.在第一季度將其在 Merus 的持股比例提高了 21.9%。GF Fund Management CO. LTD.現在擁有 1,753 股生物技術公司的股票，價值 74,000 美元，此前在上個季度增持了 315 股。Caitong International Asset Management Co. Ltd 在第一季度將其在 Merus 的持股比例提高了 955.3%。Caitong International Asset Management Co. Ltd 現在擁有 1,794 股生物技術公司的股票，價值 76,000 美元，此前在上個季度增持了 1,624 股。最後，Mirae Asset Global Investments Co. Ltd.在第二季度將其在 Merus 的持股比例提高了 15.7%。Mirae Asset Global Investments Co. Ltd.現在擁有 2,674 股生物技術公司的股票，價值 141,000 美元，此前在上個季度增持了 362 股。目前 96.14% 的股票由機構投資者持有。</p>
</div><h2>Merus Company Profile</h2>
<div class="lb-trans"><h2>Merus 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.</p>
<div class="lb-trans"><p>Merus N.V.是一家臨牀階段的免疫腫瘤學公司，專注於在荷蘭開發抗體治療。其雙特異性抗體候選藥物管線包括 Zenocutuzumab（MCLA-128），該藥物正在進行針對轉移性乳腺癌和去勢抵抗性前列腺癌患者的二期臨牀試驗，同時也在進行針對攜帶 Neuregulin 1 的實體腫瘤的 1/2 期臨牀試驗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Merus</li>
<li>What is a Death Cross in Stocks?</li>
<li>5 Healthcare Plays Powering the Sector’s Big Comeback</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>Rocket Lab: A Space Giant Hitting New Highs—Time to Chase?</li>
<li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025</li>
<li>Lowe’s vs. Home Depot: Which Benefits More From Lower Rates?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Merus 更好</li>
<li>股票中的死亡交叉是什麼？</li>
<li>5 只醫療保健股票推動該行業的大反彈</li>
<li>股票回購是什麼？投資者的全面指南</li>
<li>火箭實驗室：一家太空巨頭創下新高——現在是追逐的時候嗎？</li>
<li>2025 年有潛力上漲的 2 只 CRM 平台股票</li>
<li>Lowe’s 與 Home Depot：哪家從降低利率中受益更多？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=MRUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Merus Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Merus 嗎？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Merus 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Merus 並不在名單上。</p>
</div><p>While Merus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Merus 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Merus（NASDAQ:MRUS）被 Weiss Ratings 評為賣出（D-）評級